3 Pressing Questions for the U.S. Marijuana Industry in 2018

There have been few, if any, industries hotter than legal marijuana in the stock market this year. A majority of publicly traded marijuana stocks with a market cap of $200 million or greater have seen their valuations at least double over the past year.

Topping the list of catalysts behind these gains have been robust sales growth figures and growth projections. For instance, Marijuana Business Daily's newest report, "Marijuana Business Factbook 2017," suggests that legal weed sales could grow by 30% in the U.S. in 2017, another 45% in 2018, and by an aggregate of 300% between 2016 and 2021 to $17 billion. With few industries demonstrating such consistent growth, marijuana stocks have become a favorite of U.S. investors.

A person holding cannabis leaves in their cupped hands.
A person holding cannabis leaves in their cupped hands.

Image source: Getty Images.

We've also seen a major shift in the way the public views cannabis. Gallup, which has been surveying the public on pot for nearly 50 years, reported that a record number of respondents (64%) are now in favor of seeing marijuana legalized, as of October 2017. Comparatively, just 25% of respondents felt this way back in 1995, the year before California became the first state to legalize medical cannabis for compassionate use cases.

Despite all of this, cannabis remains an illegal (Schedule I) substance at the federal level, constraining the ability of U.S.-based pot companies to succeed.

With this in mind, here are the three most pressing questions for the U.S. marijuana industry heading into 2018.

1. Will Jeff Sessions tee off on the marijuana industry?

Probably the biggest question on the minds of the entire pot industry is what's going to happen with Attorney General Jeff Sessions and his hell-bent quest to prosecute marijuana businesses currently operating in states that have passed legal weed laws?

Attorney General Jeff Sessions giving a speech.
Attorney General Jeff Sessions giving a speech.

Image source: Jeff Sessions' Senate webpage.

Sessions has made no secret of his feelings about marijuana's expansion. He's been quoted as saying that "good people don't smoke marijuana," and has suggested that medical cannabis isn't an appropriate substitute to fix the opioid crisis. In May, he sent a letter to a few of his congressional colleagues requesting that they repeal the Rohrabacher-Farr Amendment. This is what disallows the Justice Department from using federal funds to prosecute marijuana businesses operating in legal states.

What's worth noting is that this amendment, now known as the Rohrabacher-Blumenauer Amendment, was blocked from vote by the GOP-controlled House Rules Committee in September, leaving it out of federal budget discussions at the time. This amendment needs to be approved each year in order to keep the Justice Department from using federal dollars to prosecute U.S. pot businesses. The Senate could always add it to their federal spending proposal, but the chance that it could be excluded from future federal spending bills is arguably higher than it's ever been.